SAN DIEGO, May 2 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today that it has been issued two patents by the U.S. Patent and Trademark Office for technologies related to genetic analysis. U.S. Patent 6,884,584, "Hybridization and Mismatch Discrimination Using Oligonucleotides Conjugated to Minor Groove Binders," claims the use of Nanogen's MGB probes on traditional solid phase support. An unrelated patent, U.S. Patent No. 6,887,362, "Dielectrophoretic Separation and Immunoassay Methods on Active Electronic Matrix Devices" relates to devices and methods for performing active, multi-step molecular and biological sample preparation and diagnostic analyses employing immunochemical techniques. Nanogen's growing intellectual property portfolio now includes 117 U.S. patents. The '584 patent for the minor groove binder technology relates to conjugates between a minor groove binding molecule and an oligonucleotide, which are used as probes to facilitate various analytic and diagnostic procedures. The application covered by this patent utilizes a "capture down" approach, where a target nucleic acid, immobilized directly or indirectly to a solid support such as glass, is detected with a minor groove binder oligonucleotide probe. Minor groove binder technology is based on a potent class of naturally occurring antibiotics that bind to the minor groove of double stranded DNA. When attached to either the 5' or 3' terminus of DNA probes, hydrophobic binding of minor groove binder molecules to the minor groove stabilizes the DNA duplex formed by these probes hybridizing to their complementary targets. This allows the use of shorter probes with higher sensitivity to mismatches. Nanogen's minor groove binder probe technology greatly improves the performance of hybridization-based systems for genetic analysis, including the detection of single nucleotide polymorphisms, the measurement of DNA and RNA isolates and allows the generation of highly sensitive gene expression systems. The '362 patent relates to bioparticle separation, bioparticle enrichment and electric field-mediated immunochemical detection on active electronic matrix devices utilizing electric fields. The invention relates to devices and methods for sample preparation, manipulation, immunoimmobilization and immunoassays, all of which can be conducted on one or more active electronic chip devices within a single system. These manipulations are useful in a variety of applications, including, for example, detection of pathogenic bacteria and biological warfare agents, point-of-care diagnostics, food or medical product quality control assays, and other biological assays. "These patents further strengthen our position as a technology leader in the genetic analysis market," said Howard C. Birndorf, Nanogen's chairman of the board and CEO. "Our minor groove binding technology, which is part of the MGB Eclipse(TM) Probe Systems and MGB Eclipse(TM) Detection reagents, provides product differentiation and superior performance for our research and clinical customers employing widely-used real-time PCR applications for molecular and gene-expression analysis." About Nanogen, Inc. Nanogen's advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop diagnostic tests for variety of diseases. Nanogen also offers a broad portfolio of patented nucleic acids chemistries and molecular tools that accelerate genomic analysis and are compatible with many systems. The SynX subsidiary offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen's website at www.nanogen.com. Nanogen Forward-Looking Statement This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.